ID: toremifene
Aliases: toremifene citrate, Fareston
Type: compound
Route/form: oral
Status: approved
Evidence level: approved / labelled
Best data tier: approved label + human controlled/review
Support scope: human
Source types: human_trial, label, meta_analysis
Linked sources: 3
Broad outcomes: Hormones / fertility / sexual health
Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.
Targets / mechanism
- estrogen receptor modulator
- ER antagonist in breast tissue
Optimization domains
- SERM
- breast cancer
- endocrine
- PCT discussions
Research basis
- Optimization angle: toremifene is a tamoxifen-adjacent SERM that appears in PCT and male fertility discussions because it can affect the hypothalamic-pituitary-testicular axis.
- A small human oligozoospermia source is more relevant to performance-endocrine curation than the breast-cancer label alone.
Limits, risks, and missing evidence
- QT prolongation, thromboembolic risk, hepatic considerations, and pregnancy toxicity require label-level caution.
- PCT use is off-label and not proof that an androgenic cycle was safe or recoverable.
Risk flags
- prescription only
- qt risk
- thrombotic risk
- off label male context
Linked papers, labels, and reviews
- DailyMed label: FARESTON toremifene citrate tablet
label / dailymed_toremifene_label
Approved SERM label for metastatic breast cancer in postmenopausal women. - Meta-analysis of trials comparing toremifene with tamoxifen in postmenopausal women with breast cancer
meta_analysis / pubmed_toremifene_breast_cancer_meta_1999
Clinical breast-cancer SERM evidence base; relevant to approved oncology context, not proof of PCT utility. - The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters
human_trial / pubmed_toremifene_oligozoospermia_2007
Male oligozoospermia study showing gonadotropin/testicular-axis effects; adjacent to PCT discussions but not a steroid-cycle recovery protocol.